The results of the pharmacosurveillance program in an oncological day hospital

• Autores: B. Marzal Alfaro, Eva González-Haba Peña, M. N. Sánchez Fresneda, Miriam Giráldez Quiroga, María Sanjurjo Sáez
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 15, Nº. 1, 2013, págs. 59-62
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: To analyze the infusion-related adverse reactions (IAR) to antineoplastic drugs reported through the Oncology Day Hospital pharmacosurveillance program. Method: Prospective, descriptive and observational study of IARs documented from January 2009 to October 2011. We analyzed those considered as serious by collecting: date, suspicious drug and chemotherapy scheme, cycle number, implementation or not of skin tests and their results, and IAR resolution. Results: We analyzed 64 IARs, 31 of them were serious (48%). Docetaxel was the main drug in non-serious IARs (27.3%) and oxaliplatinin in the serious ones (41.9%). Skin tests were carried out in 18 patients (58%). In 13 patients (42%), the drug was suspended, in 11 (35%) there was a change in therapeutic line and in seven (23%) desensitization was performed. Conclusions: Our study confirms that described in the literature about the type of drugs monitored by an Intensive Surveillance Program of an oncology day hospital